Glaukos stock snapshot after recent trading pullback

Glaukos (GKOS) has drawn investor attention after recent trading, with the stock down about 14% over the past week and roughly flat over the past month despite a year to date gain.

At a last close of US$120.23 and an implied market value of about US$7.1b, the ophthalmic therapy company sits at an interesting point for investors weighing short term volatility against its longer term share price record.

The sharp 13.5% one day share price decline and 16.5% drop over the past week contrast with Glaukos' 25.2% one year total shareholder return and 119.2% three year total shareholder return. This suggests recent momentum has faded after a strong multi year run.

If you are weighing what to watch next in healthcare and beyond, this pullback can be a prompt to scan other opportunities through 34 healthcare AI stocks

With Glaukos reporting annual revenue of US$551.3m, a reported loss of US$189.3m and a recent market value around US$7.1b, the key question now is whether the recent pullback leaves genuine upside or if the stock already reflects expectations for future growth.

Most Popular Narrative: 20.4% Undervalued

Glaukos' most followed narrative pegs fair value at about $151.08 per share, comfortably above the recent $120.23 close and framing the latest pullback as a potential mispricing rather than a reset.

Strong ongoing adoption and utilization of iDose TR, a first-of-its-kind procedural pharmaceutical with a unique profile, suggests the early stages of a paradigm shift toward interventional glaucoma therapies, a substantial long-term opportunity given the aging population and rising prevalence of glaucoma, potentially influencing multi-year revenue and market expansion.

Want to see what is behind that paradigm shift call and the higher fair value estimate? Revenue build, margin uplift and a premium future earnings multiple are all built into this narrative, but the exact mix might surprise you.

Result: Fair Value of $151.08 (UNDERVALUED)

However, this hinges on smooth execution, and setbacks in reimbursement decisions or clinical trial outcomes for key products could quickly challenge that undervalued narrative.

Another take on valuation

That fair value of $151.08 suggests room above the recent $120.23 price, but the P/S ratio of 12.8x tells a different story. It sits well above the US Medical Equipment industry at 2.8x, the peer average at 4.3x, and the fair ratio of 6.6x. This points to meaningful valuation risk if sentiment cools.

For a closer look at what the numbers imply if the P/S ratio drifts toward that fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed, and with both risks and rewards in play, it makes sense to look through the data yourself and move quickly while the details are fresh in mind. To see the full picture of potential upsides alongside the key concerns, take a closer look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with Glaukos, you could miss stocks that better match your style, so put the screener to work and let the data do the heavy lifting.

• Spot underappreciated quality by scanning 49 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their potential.
• Prioritise resilience by focusing on 67 resilient stocks with low risk scores that score well on stability and balance sheet strength.
• Get ahead of the crowd by hunting through a screener containing 21 high quality undiscovered gems that most investors are not watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.